Pharmaceutical group Shire is braced for a report from US regulators on the safety of drugs used to treat attention-deficit hyperactivity disorder (ADHD) which could affect almost a third of its annual sales of $3bn (£1.9bn).
Findings from the study by the food and drug administration and US department of health into ADHD medicines that use stimulants such as amphetamines are due in early August. The study was launched in 2007 amid concern about the potential for increased risk of heart attack, stroke or other cardiovascular problems when the drugs are used by children and adults.
No comments:
Post a Comment